8171 - 8180 of 8824 Results
Title
Year
-
OPENTitle: Protein network analysis links the NSL complex to Parkinson’s disease via mitochondrial and nuclear biologyJournal Name: Molecular OmicsPublisher: Oxford University Press (OUP)Vol: 19Issue #: 8Start Page: 668End Page: 679Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1039/d2mo00325bBest OA location URL: https://pubs.rsc.org/en/content/articlepdf/2023/mo/d2mo00325bCitation Count: 0
-
RESTRICTEDTitle: Amantadine in the treatment of Parkinson's disease and other movement disordersJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 12Start Page: 1048End Page: 1056Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00249-0Citation Count: 192
-
RESTRICTEDTitle: Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 1Start Page: 53End Page: 65Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00368-9Citation Count: 65
-
OPENTitle: The East Asian Parkinson Disease Genomics ConsortiumJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 12Start Page: 982End Page: 982Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00373-2Citation Count: 9
-
RESTRICTEDTitle: Movement disorders research in 2021: cracking the paradigmJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 1Start Page: 10End Page: 11Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00413-0Citation Count: 19
-
RESTRICTEDTitle: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1099End Page: 1109Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8Citation Count: 183
-
RESTRICTEDTitle: Revisiting levodopa for advanced Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1063End Page: 1065Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00435-5Citation Count: 2
-
RESTRICTEDTitle: Major advances in Parkinson's disease over the past two decades and future research directionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1076End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3Citation Count: 16
-
RESTRICTEDTitle: Inconsistency and incongruence: the two diagnostic pillars of functional movement disorderJournal Name: The LancetPublisher: Elsevier BVVol: 400Issue #: 10348Start Page: 328End Page: 328Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0140-6736(22)01184-9Citation Count: 11
-
OPENTitle: Freezing of gait and levodopaJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 7Start Page: 505End Page: 506Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00175-7Citation Count: 8